MIB Agents Family Funds support research through our annual OutSmarting Osteosarcoma research grant program. Since launching in 2017, MIB Agents Family Funds have awarded $2.5 million in osteosarcoma research funding, supporting 32 investigators. In 2022, we introduced a dedicated Young Investigator Grant, and since then, we’re proud to have supported 14 early-career scientists driving progress in the field.
SEE FUNDED RESEARCHLaunched in 2017 and powered by MIB Agents Family Funds, the OutSmarting Osteosarcoma Research Grant has fueled discovery by awarding $2.5 million to 32 dedicated investigators working to advance osteosarcoma research. But the impact of this investment extends far beyond these studies. As a result of OutSmarting Osteosarcoma's investment, MIB Agents funded studies have resulted in:
.png)
159 Presentations sharing findings with the scientific community
.png)
19 Publications disseminating findings into the public domain
.png)
7 clinical trials opened
.png)
$21.1 million secured in additional osteosarcoma research funding
.webp)
OutSmarting Osteosarcoma 2025 Hero Grant Because of Sydney
David Ulmert, MD, PhD | University of California, Los Angeles
High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches
OutSmarting Osteosarcoma 2024 Hope YI Grant Because of Sydney
Arianexys Aquino-López, MD, PhD | Baylor College of Medicine
Repurposing Virus Specific T cells as Immune Therapy for Osteosarcoma
OutSmarting Osteosarcoma 2023 Hope YI Grant Because of Sydney
Marta Roman Moreno, PhD | University of California, San Francisco
CRISPRi screening to identify vulnerabilities in metastatic osteosarcoma
.webp)
OutSmarting Osteosarcoma 2025 Hope YI Grant in partnership with the RISE Foundation, Because of Reese
Andrew S. Clugston, PhD | University of California, San Francisco Oncogenic structural variation in the genome of pediatric osteosarcoma
OutSmarting Osteosarcoma 2025 Hope YI Grant Because of Annaleigh
Joseph Skeate, PhD | University of Minnesota
Next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma
OutSmarting Osteosarcoma 2023 Hero Grant Because of Annaleigh in collaboration with Fishin' for the Cure
Heather Gardner, DVM, PhD, DACVIM (Oncology) | Tufts University
Liquid biopsy platforms to support early detection of metastasis and inform future interventions in osteosarcoma
OutSmarting Osteosarcoma 2023 Hero Grant Because of Annaleigh
Sam Volchenboum, MD, PhD | University of Chicago
Data commons to support new treatments for osteosarcoma
OutSmarting Osteosarcoma 2024 Hope YI Grant Because of Ava
Chelsey Burke, MD | Stanford University
Evaluating tumor evolution and mechanisms of resistance in osteosarcoma
OutSmarting Osteosarcoma 2025 Hope YI Grant Because of Buddy
Janeala Morsby, PhD | St. Jude Children's Research Hospital
Synergy of ATM and PARP inhibitors in pediatric osteosarcoma
OutSmarting Osteosarcoma 2022 Hope YI Grant Because of Dylan
John Ligon, MD | University of Florida
RNA-nanoparticle vaccines to overcome the immunosuppressive tumor microenvironment of canine osteosarcoma
OutSmarting Osteosarcoma 2025 Hope YI Grant Because of Isaac
Ali Cihan, PhD | Memorial Sloan Kettering Cancer Center
Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma
OutSmarting Osteosarcoma 2024 Hope YI Grant Because of Charlotte
Betsy Young, MD | University of California, San Francisco
Tumor-intrinsic cGAS-STING activation promotes anti-tumor inflammatory response in osteosarcoma
OutSmarting Osteosarcoma 2023 Hope YI Grant Because of Charlotte
Amanda Marinoff, MD | University of California, San Francisco
Novel molecular biomarkers for risk stratification in pediatric osteosarcoma
OutSmarting Osteosarcoma 2022 Hope YI Grant Because of Charlotte
Eunice Lopez-Fuentes, PhD | University of California, San Francisco
Two epigenetically distinct cellular states in osteosarcoma, defined by a cluster-specific set of pioneer transcription factors and show differential drug response
OutSmarting Osteosarcoma 2022 Hope YI Grant Because of Charlotte
Kristen VanHeyst, DO | UH Rainbow Babies and Children’s Hospital
Modulating TGF-beta Signaling in the tumor microenvironment as an effective therapy for osteosarcoma
